Drug
Nicoderm C-Q Transdermal Product
Nicoderm C-Q Transdermal Product is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
2(67%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_4
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 4
Trials by Phase
Phase 42 (66.7%)
N/A1 (33.3%)
Trials by Status
terminated267%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_4
Mindfulness Based Smoking Cessation Among Cancer Survivors
NCT04038255
completedphase_4
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
NCT03999411
terminatednot_applicable
Cytisine Compared to Combination NRT in Relapsed Smokers
NCT04286295
Clinical Trials (3)
Showing 3 of 3 trials
NCT04038255Phase 4
Mindfulness Based Smoking Cessation Among Cancer Survivors
NCT03999411Phase 4
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
NCT04286295Not Applicable
Cytisine Compared to Combination NRT in Relapsed Smokers
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3